Despite mifepristone’s broad medical promise, its development has been repeatedly stymied by abortion opponents who fear wider availability would weaken their attempts to suppress abortion access.
More than 26 million women in the U.S. are affected by fibroids, which are noncancerous growths of the uterus that can reach the size of a grapefruit or larger. Treatment too often defaults to invasive surgery, either removing the fibroids or performing hysterectomies.
In China today, a three-month regimen of 10 milligrams per day is the approved protocol for treating fibroids. Meanwhile, American women still do not have access to this very effective nonsurgical treatment.
This is Part 1 of 3 in a new series, “The Moral Property of Women: How Antiabortion Politics Are Withholding Medical Care,” a serialized version of the Winter 2026 print feature article.








